CA3196642A1 - Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof - Google Patents

Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof

Info

Publication number
CA3196642A1
CA3196642A1 CA3196642A CA3196642A CA3196642A1 CA 3196642 A1 CA3196642 A1 CA 3196642A1 CA 3196642 A CA3196642 A CA 3196642A CA 3196642 A CA3196642 A CA 3196642A CA 3196642 A1 CA3196642 A1 CA 3196642A1
Authority
CA
Canada
Prior art keywords
formula
compound
group
reaction
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3196642A
Other languages
English (en)
French (fr)
Inventor
Christian GRUGEL
Tobias Wedel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actinogen Medical Ltd
Original Assignee
Actinogen Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020904060A external-priority patent/AU2020904060A0/en
Application filed by Actinogen Medical Ltd filed Critical Actinogen Medical Ltd
Publication of CA3196642A1 publication Critical patent/CA3196642A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B49/00—Grignard reactions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3196642A 2020-11-06 2021-11-05 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof Pending CA3196642A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020904060A AU2020904060A0 (en) 2020-11-06 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof
AU2020904060 2020-11-06
PCT/AU2021/051310 WO2022094668A1 (en) 2020-11-06 2021-11-05 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof

Publications (1)

Publication Number Publication Date
CA3196642A1 true CA3196642A1 (en) 2022-05-12

Family

ID=81458249

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3196642A Pending CA3196642A1 (en) 2020-11-06 2021-11-05 Process for preparing heterocyclic methanone compounds and aza-bicyclo intermediates thereof

Country Status (11)

Country Link
US (1) US20230416243A1 (cg-RX-API-DMAC7.html)
EP (1) EP4240740A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023548368A (cg-RX-API-DMAC7.html)
KR (1) KR20230154789A (cg-RX-API-DMAC7.html)
CN (1) CN116981461A (cg-RX-API-DMAC7.html)
AU (1) AU2021374232A1 (cg-RX-API-DMAC7.html)
CA (1) CA3196642A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001300A1 (cg-RX-API-DMAC7.html)
IL (1) IL302671A (cg-RX-API-DMAC7.html)
MX (1) MX2023004940A (cg-RX-API-DMAC7.html)
WO (1) WO2022094668A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026509196A (ja) * 2023-03-02 2026-03-17 アクチノゲン メディカル リミテッド アザ二環式ヘテロアリール化合物を調製するための流動化学プロセス
CN121969372A (zh) * 2023-10-03 2026-05-01 射线质医疗有限公司 片剂制剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1732552A4 (en) * 2004-01-20 2007-12-19 Merck & Co Inc 2,6-DISUBSTITUTED PIPERIDINES AS MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
MY145633A (en) * 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ES2366058T3 (es) * 2006-03-01 2011-10-14 Theravance, Inc. Compuestos de 8-azabiciclo[3.2.1]octano como antagonistas de los receptores opioides mu.
CA2738453C (en) * 2008-10-23 2017-07-04 Boehringer Ingelheim International Gmbh Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use
DK2477983T3 (en) * 2009-09-16 2015-06-29 Univ Edinburgh (4-phenyl-piperidin-1-yl) - [5-1H-pyrazol-4-yl) -thiophene-3-yl] -METHANONFORBINDELSER AND THEIR USE
AU2010331927B2 (en) * 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
WO2011090935A1 (en) * 2010-01-19 2011-07-28 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
BR112012027640B1 (pt) * 2010-04-29 2021-08-03 The University Of Edinburgh Composto, composição farmacêutica, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1

Also Published As

Publication number Publication date
EP4240740A4 (en) 2024-12-11
US20230416243A1 (en) 2023-12-28
CN116981461A (zh) 2023-10-31
EP4240740A1 (en) 2023-09-13
IL302671A (en) 2023-07-01
MX2023004940A (es) 2023-09-12
AU2021374232A9 (en) 2024-09-26
WO2022094668A1 (en) 2022-05-12
CL2023001300A1 (es) 2024-01-05
JP2023548368A (ja) 2023-11-16
KR20230154789A (ko) 2023-11-09
AU2021374232A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
ES2956288T3 (es) Métodos y productos intermedios para preparar un compuesto terapéutico útil en el tratamiento de infección vírica por Retroviridae
US20240059678A1 (en) Synthesis Method for Aminopyrimidine FAK Inhibitor Compound
TW201713652A (zh) 雜環化合物的合成
CN102329325B (zh) 吡咯并嘧啶酮类dpp-iv抑制剂
CN106946917A (zh) 一种jak抑制剂巴瑞替尼及其中间体的新合成方法
EP3766869A1 (en) Simple preparation method for avibactam
EP3733648B1 (en) Method for preparing 5r-benzyloxyaminopiperidin-2s-carboxylic acid or derivative thereof
US11926633B2 (en) Synthesis methods for upadacitinib and intermediate thereof
US20230416243A1 (en) Process for Preparing Heterocyclic Methanone Compounds and AZA-Bicyclo Intermediates Thereof
JP2026082843A (ja) 合成方法及び中間体
CN102725288A (zh) 用于制造6-取代的1-甲基-1h-苯并咪唑衍生物的方法和所述方法的中间体
EP3543236A1 (en) Method for preparing avibactam intermediate
EP2841419A1 (en) Crystalline forms of saxagliptin
CN108658851B (zh) 2-氯-3-甲基-6-酰基氨基吡啶及其制备方法和用途
US20210147466A1 (en) Improved processes for the preparation of guadecitabine and intermediates thereof
CN104876872A (zh) 一种制备1-叔丁氧基羰基-3-羟甲基吲唑的方法及应用
US9085569B2 (en) 1,2,4-oxadiazol derivatives, process for their preparation and use thereof as intermediates in the preparation of indolic alkaloids
CA3268617A1 (en) Synthesis methods and intermediates
US20260001882A1 (en) Process for preparing bicyclic glycine-proline compounds and monocyclic glycine-proline intermediates thereof
US20250304538A1 (en) Process of preparing remibrutinib substantially free of nitrosamine impurity
CN105121417B (zh) 经取代噻唑基乙酸三乙胺盐的结晶型
CN102924332B (zh) N-p-双酸氨基酸单酯的合成工艺改进
JP2013010735A (ja) 1,2,4−トリアゾール化合物及びグアニジン誘導体の合成方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240902

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240902

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240902

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251006

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251006

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251104

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251104

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260105

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260105

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260122